Navigation Links
Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
Date:11/11/2013

SAN FRANCISCO, Nov. 11, 2013 /PRNewswire/ -- Channel Medsystems has received investigational testing authorization from Health Canada to begin enrolling patients in the Cryoablation Feasibility Trial (CRYSTAL), a multi-site clinical trial designed to evaluate its innovative cryothermic treatment for heavy menstrual bleeding due to benign causes.  The CRYSTAL study is designed to evaluate the efficacy and tolerability of Channel Medsystems' in-office cryothermic procedure. The Company expects to enroll its first patient in November.

(Logo: http://photos.prnewswire.com/prnh/20131111/SF14418LOGO)

One in five women suffers from heavy menstrual bleeding, impacting both their health and quality of life. In the US, global endometrial ablation (GEA) is the most common procedure for treating heavy menstrual bleeding.   Existing GEA procedures are typically performed in a hospital or outpatient surgical center and often require general anesthesia or conscious sedation to reduce discomfort during treatment.   Recovery times and outcomes are often highly dependent on the technology used, the skill of the physician and the anesthesia regimen elected.

Channel Medsystems' cryothermic device was developed to provide patients suffering from heavy menstrual bleeding -- and the physicians who treat them -- the option of an effective, safe and well-tolerated treatment that can be easily incorporated into the physician's office practice.  The technology uses cryothermic energy that gynecologists have relied on for years to perform delicate procedures. The two-and-a-half minute treatment takes advantage of the analgesic effect of cold energy and early clinical results suggest that Channel's cryothermic procedure can be comfortably done with minimal anesthesia.

"Our mission is to develop procedures that are effective, safe and well-tolerated under minimal anesthesia.  We believe our innovative delivery of cryothermic energy provides an excellent platform to treat heavy menstrual bleeding and we are excited to validate this application in our CRYSTAL clinical trial. Ultimately, we believe our technology will accelerate the transition of GEA procedures into the office setting, which in turn should translate into significant cost reductions for the healthcare system," said Ric Cote, President and CEO of Channel Medsystems.

Channel Medsystems also announced it has hired Mary Edwards, one of the top clinical and regulatory experts in the field of women's health, to run its North American trial and to serve as the Company's Senior Vice President of Clinical and Regulatory Affairs.  "Throughout my career, I have been a passionate advocate for technologies and procedures that benefit women," said Ms. Edwards.  "Our technology couples the gentle and safe profile of cryothermic energy with an intelligent system that supports precision and ease of use.  I am excited to be in a position where I can help bring a much-needed innovation to women suffering with heavy menstrual bleeding."

About the Cryothermic Technology Platform: Channel Medsystems' novel cryothermic technology and streamlined delivery system were developed with feedback from leading clinicians and biomedical engineers at the healthcare incubator, Theranova. The technology integrates cryothermic energy and the user controls into a self-contained, hand held device, eliminating the need for a separate control unit or capital equipment. 

About Channel Medsystems:  Channel Medsystems is a venture-backed company that was founded to bring innovation to the delivery of women's healthcare. The Company strives to develop treatments to meet the unique needs of female patients and the high standards of their healthcare providers. Channel Medsystems is committed to ensuring that patients have access to high quality outcomes that can be delivered in the convenience and comfort of their healthcare provider's office. For more information, please visit www.channelmedsystems.com.

CAUTION: This device is available for investigational use in Canada.  It is not available for sale or investigational use in the United States.


'/>"/>
SOURCE Channel Medsystems
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SoundConnect Launches Innovative Channel Partner Webinar Series
2. ReachMD Radio Joins Clear Channel’s iHeartRadio
3. Multichannel Pipettes Promotion Now Available at Pipette.com
4. Discovery Channel MythBuster Star Jaime Vendera First Person on Record to Break a Glass with His Voice Endorses UV-Aid by UV Technologies, LLC
5. New from Cole-Parmer: Ismatec Reglo Independent Channel Control Peristaltic Pump
6. SoundConnect Named Adobe Connect Channel Partner
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. ReachMD on XM Satellite Radio Moves to Channel 245 Effective May 9, 2013
9. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
10. NSG Announces New Quartz Micro Flow Channel
11. Amarantus Bioscience Launches Online Corporate Communication Channels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):